Biologic gets new indication for Crohn's disease
Adalimumab (Humira, Abbott) is now approved for a second indication for use by patients with moderately to severely active Crohn's disease who are not responding to conventional therapy to reduce signs and symptoms and induce and maintain clinical remission. The new approval was based on results from three clinical trials in more than 1,400 adult patients and evaluated the efficacy of adalimumab in patients who were naive to anti-tumor necrosis factor alpha therapy. According to Abbott, this approval marks the indication to launch with the Humira Pen, a method of self-injection approved by the FDA in June 2006. Adalimumab was previously approved for reducing the signs and symptoms and inducing clinical remission in patients who have lost response or have become intolerant to infliximab (Remicade, Centocor).
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Challenges for Pharmacies in 2025: What to Expect and How to Prepare
January 8th 2025Pharmacy professionals are used to overcoming obstacles in this competitive, dynamic field. But the coming year will bring challenges affecting patient care, the industry workforce and their business. Pharmacies must be ready to do more than weather the storm; they need deliberate strategy and sophisticated tools to thrive amidst these obstacles. This white paper will discuss the issues and solutions that should be at the top of every pharmacy professional’s mind as they start the new year.
